Search results for "From ACP Internist"
Expert panel recommends SGLT2 inhibitor or GLP-1 receptor agonist for patients with type 2 diabetes and CVD
The American College of Cardiology's new decision pathway also calls for repeated HbA1c screening and detailed clinician-patient risk discussions for patients with cardiovascular disease (CVD) who are diagnosed with type 2 diabetes.
https://diabetes.acponline.org/archives/2018/12/14/9.htm
14 Dec 2018
Kidney failure, CV events lower with canagliflozin than placebo, industry study finds
The trial was stopped early after an interim safety analysis found significantly better renal and cardiovascular outcomes among type 2 diabetes patients randomized to canagliflozin than those assigned to placebo.
https://diabetes.acponline.org/archives/2019/05/10/10.htm
10 May 2019
Weight loss program may improve HbA1c more than typical diabetes nutrition counseling, study finds
Patients participating in Weight Watchers program supplemented with diabetes education lost more weight than a control group by 3, 6, 9, and 12 months of follow-up.
https://diabetes.acponline.org/archives/2016/11/11/8.htm
11 Nov 2016
ACP recommends less intensive glucose control in most cases of type 2 diabetes
The evidence-based guidance statement from ACP calls for personalized goals and an HbA1c target between 7% and 8% for most patients with type 2 diabetes.
https://diabetes.acponline.org/archives/2018/03/09/6.htm
9 Mar 2018
Diabetes outcomes similar when primary care provided by NPs, PAs, or physicians, study finds
More care by nurse practitioners (NPs) and physician assistants (PAs) may be a way to expand primary care access while maintaining quality standards.
https://diabetes.acponline.org/archives/2018/12/14/10.htm
14 Dec 2018
Once-weekly insulin had similar effects to daily insulin in type 2 diabetes, industry-funded trial finds
HbA1c levels improved by more than a point in insulin-naive patients with inadequately controlled type 2 diabetes who were randomized to a weekly 70-U dose of an investigational insulin.
https://diabetes.acponline.org/archives/2020/10/09/8.htm
9 Oct 2020
New guideline offers recommendations for older patients with diabetes or prediabetes
The Endocrine Society's new clinical practice guideline recommends lifestyle therapy, then metformin, then second-line drugs (but not sulfonylureas and glinides) or insulin for diabetes patients ages 65 years and older, among other advice.
https://diabetes.acponline.org/archives/2019/04/05/6.htm
5 Apr 2019
Canagliflozin may not increase fracture risk in patients at low risk for fractures
Although canagliflozin has been linked to decreased bone mineral density, patients with type 2 diabetes who initiated the drug had similar risk of a first fracture as those who started a glucagon-like peptide-1 receptor agonist.
https://diabetes.acponline.org/archives/2019/01/11/7.htm
11 Jan 2019
Thinking about drug costs and basal insulin in type 2 diabetes
Two articles in the May ACP Internist focused on patients with type 2 diabetes—a cover story explained why and how internists should consider patients' drug costs and the latest Pearls from I.M. Peers talked about basal insulin.
https://diabetes.acponline.org/archives/2022/05/13/7.htm
13 May 2022
Primary care-based weight-loss program led to remission of type 2 diabetes
At the end of 12 months, 36 intervention participants lost 15 kg or more, compared to no participants in the control group, and diabetes remission was associated with the amount of weight lost.
https://diabetes.acponline.org/archives/2018/01/12/11.htm
12 Jan 2018